Adozelesin, formerly known as U 73975 or adolezesin, is an experimental antitumor drug of the duocarmycin class. Adozelesin is the first of a class of DNA-sequence-selective alkylating agents, the cyclopropa(c)pyrrolo(3,2-e)indol-4(5H)-ones (CPls), that have been shown to have of potent inhibitory properties of DNA synthesis. It binds to and alkylates DNA, resulting in a reduction of both cellular and simian virus 40 (SV40) DNA replication which ultimately reduces the rate of cancer growth. Phase I and Phase II clinical trials were conducted in 2000s, however, it was found adozelesin had marginal efficacy in the treatment of metastatic breast cancer at the dosage and schedule used. References: Hopton SR, Thompson AS. Manipulative interplay of two adozelesin molecules with d(ATTAAT)2achieving ligand-stacked Watson-Crick and Hoogsteen base-paired duplex adducts. Biochemistry. 2011 May 17;50(19):4143-54. doi: 10.1021/bi101945a. Epub 2011 Apr 19. PubMed PMID: 21469674.

纯度：≥98%

CAS：110314-48-2